Pathology and Laboratory Medicine
DNA repair, BRCA1, breast and ovarian cancer, radioation biology.
I graduated from the University of Kansas with a B.S. in Cell Biology in 2006. While at KU, I studied the adenomatous polyposis coli (APC) tumor suppressor gene and its role in colorectal carcinogenesis in the laboratory of Kristi Neufeld, Ph.D. It was this experience and the wonderful mentorship that I received that ignited my passion for cancer biology and fueled my interest in pursuing the dual M.D./Ph.D. degrees.
My clinical and research interests remain in tumor biology and cancer medicine. I completed my doctoral research in the laboratory of Roy Jensen, M.D., with co-mentorship from Fariba Behbod, Pharm.D., Ph.D., in the Department of Pathology & Laboratory Medicine and The University of Kansas Cancer Center. My research focused on exploiting and manipulating BRCA1-dependent DNA double-strand break (DSB) and interstrand crosslink (ICL) repair. DSBs and ICLs are toxic genetic lesions that are induced by ionizing radiation and certain chemotherapeutic agents. My studies identified a clinically-viable mechanism to manipulate homologous recombination and non-homologous end-joining, two major pathways responsible for repair of DSB and ICL lesions. I have also been active in designing and conducting several clinical studies evaluating the potential use of DNA repair biomarkers as predictors of response to neo-adjuvant and adjuvant chemotherapy in triple-negative breast cancer.
Shane Stecklein, Ph.D.